To meet the development needs of the healthcare industry and help companies better mitigate business risks, CBI China was invited by the Daiichi-Sankyo to participate in the compliance week training and share compliance experiences. This training aims to promote the construction of a compliance system, establish a sound pharmaceutical compliance system and culture, and discuss the legal risks and preventive measures that may exist in current medical cooperation. Over 50 employees from the Daiichi-Sankyo attended the training on-site, and more than 50 colleagues watched the entire training conference through live streaming. Nick Hao, the Operation Director of CBI China, shared compliance management experiences.
 

Nick provided a detailed introduction and training to the Daiichi-Sankyo team on "HCO due diligence." He gave professional and detailed explanations on social organizations, compliance risks in social organizations, HCO DD, and answered questions from the attendees.
 

The training started with the definition of social organization. Nick presented relevant professional content to colleagues from the first and third departments through multiple dimensions. He shared valuable industry data, allowing the participants to have a clear understanding of the important background knowledge of this training.
 

Regarding the content of compliance risk points for social organizations, Nick conveys the relevant knowledge points through rigorous summarization and organization, in a complete and professional manner. By sharing common compliance risk points, the important compliance value of HCO DD in the pharmaceutical industry is determined.

Finally, Nick shared CBI China's professional and reliable HCO compliance review program, detailing the difficulties of HCO compliance review, the necessity of compliance review, and the solutions for compliance review. He combined vivid case studies from different levels to give the attendees of the Daiichi-Sankyo Conference a new and intuitive understanding.
 

Innovation, integrity, and accountability are the core values of the Daiichi-Sankyo's culture and the key to the company's sustainable success. This aligns with CBI China's corporate mission of "pursuing truth, building trust" without any deliberate planning. In the future, CBI China will strive to promote sincere cooperation with more pharmaceutical industry partners, work together, keep up with industry trends and relevant policies, continuously improve its own database and business processes, evaluate the company's own risk factors, propose optimization compliance recommendations and solutions, and promote the rational and orderly development of the pharmaceutical industry.
 

The CBI Orbit system takes a full lifecycle management perspective on business relationships and utilizes multidimensional identification. With a due diligence system at its core, it conducts comprehensive monitoring of risks associated with entities, completes continuous due diligence investigations on clients, and meets users' ongoing risk identification needs. It also effectively retains traces of due diligence operations and management through various forms such as risk notifications and operation logs, thereby reducing cooperation risks.